Jurgi Camblong Sells 20,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00. Following the sale, the chairman owned 3,492,822 shares in the company, valued at $23,157,409.86. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.62, for a total transaction of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.25, for a total value of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total value of $44,540.00.

SOPHiA GENETICS Stock Down 1.2%

Shares of NASDAQ SOPH traded down $0.07 during midday trading on Tuesday, hitting $5.58. 56,495 shares of the company’s stock were exchanged, compared to its average volume of 200,351. The firm’s fifty day simple moving average is $5.40 and its 200-day simple moving average is $5.08. The company has a market cap of $468.19 million, a PE ratio of -10.74 and a beta of 0.96. SOPHiA GENETICS SA has a twelve month low of $2.92 and a twelve month high of $6.77. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. Research analysts predict that SOPHiA GENETICS SA will post -0.58 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC raised its holdings in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after buying an additional 9,800 shares during the period. Archon Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after buying an additional 14,342 shares during the period. Finally, Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth about $2,157,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Finally, HC Wainwright started coverage on SOPHiA GENETICS in a research report on Monday, July 20th. They issued a “buy” rating and a $12.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Hold” and an average price target of $9.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.